Immunogenicity of the HPV-6, 11, 16, 18 Vaccine Among Adolescent Girls Who Receive Vaccine Doses at Non-recommended Intervals and Factors Related to Non-adherence.
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics
- 07 Feb 2018 Results published in the Vaccine.
- 07 Feb 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 10 Jun 2010 Actual initiation date (June 2010) added as reported by ClinicalTrials.gov.